Results 11 to 20 of about 197,499 (175)

Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement.

J Clin Endocrinol Metab
Abstract Context Several long-acting growth hormone (LAGH) therapies have recently become available, but guidance on their usage in children with growth hormone (GH) deficiency is limited. Methods International experts in pediatric ...
Maniatis A, Cutfield W, Dattani M, Deal C, Collett-Solberg PF, Horikawa R, Maghnie M, Miller BS, Polak M, Sävendahl L, Woelfle J.   +10 more
europepmc   +5 more sources

Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.

J Clin Endocrinol Metab, 2020
AbstractContextLong-acting GH (LAGH) preparations are currently being developed in an attempt to improve adherence. The profile of GH action following administration of LAGH raises practical questions about clinical monitoring and long-term safety and efficacy of these new therapeutic agents.MethodsRecent literature and meeting proceedings regarding ...
Miller BS, Velazquez E, Yuen KCJ.
europepmc   +6 more sources

Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis

Pharmacological Research, 2023
We evaluated the efficacy, safety, adherence, quality of life (QoL) and cost-effectiveness of long-acting growth hormone (LAGH) vs daily growth hormone (GH) preparations in the treatment of growth hormone deficiency (GHD) in children. Systematic searches
Chiara Mameli, Massimiliano Orso, Valeria Calcaterra, Malgorzata Gabriela Wasniewska, Tommaso Aversa, Simona Granato, Pietro Bruschini, Liliana Guadagni, Daniela d’Angela, Federico Spandonaro, Barbara Polistena, Gianvincenzo Zuccotti   +11 more
doaj   +3 more sources

Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency. [PDF]

World J Clin Cases, 2023
β cells are the main cells responsible for the hypoglycemic function of pancreatic islets, and the insulin secreted by these cells is the only hormone that lowers blood glucose levels in the human body. β cells are regulated by various factors, among which neurotransmitters make an important contribution.
Xia W, Wang T, Pan JY.
europepmc   +3 more sources

Treatment of a case with short stature and Goltz syndrome with long-acting growth hormone: a case report and follow-up [PDF]

BMC Pediatrics
Goltz syndrome, also known as focal dermal hypoplasia, is an X-linked dominant genetic disorder caused by mutations in the PORCN gene, mainly characterized by developmental impairments affecting the skin, hair, bones, teeth, and eyes.
Jinghui Zhang, Nana Qiao, Xiaochun Li
doaj   +2 more sources

Delphi-based Spanish consensus on the use of long-acting growth hormone in pediatric growth hormone deficiency: recommendations from the ConverGHe Working Group [PDF]

Frontiers in Endocrinology
BackgroundLong-acting growth hormone (LAGH) formulations have emerged as an alternative to daily recombinant human growth hormone (rhGH) in pediatric growth hormone deficiency (GHD).
Lidia Castro-Feijóo, José-Ignacio Labarta-Aizpún, Marta Ramon-Krauel, Diana Primiano, Diego Yeste Fernández, Isabel González Casado   +5 more
doaj   +2 more sources

Long-acting growth hormone for pediatric GHD: insights into molecular modification and clinical application [PDF]

Frontiers in Endocrinology
Long-acting growth hormone (LAGH) therapies represent a paradigm shift in the management of growth hormone deficiency (GHD), alleviating the burden of daily injections.
Jianyang Gu, Jianyang Gu, Yongbo Qiao, Ping Gong   +3 more
doaj   +2 more sources

Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone [PDF]

Children
Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat,
Atilla Büyükgebiz, And Demir
doaj   +2 more sources

Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis [PDF]

Scientific Reports
The purpose of this study is to compare the relative efficacy and safety of long-acting growth hormone (LAGH) as a growth hormone replacement therapy in prepubertal children with growth hormone deficiency (GHD).
Jianfang Zhu, Ke Yuan, Sunita Rana, Satya Lavanya Jakki, Amit Subray Bhat, Li Liang, Chunlin Wang   +6 more
doaj   +2 more sources

First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry [PDF]

Orphanet Journal of Rare Diseases
The development of long-acting growth hormone (LAGH) formulations offers a promising approach to reduce injection frequency and to improve adherence in growth hormone deficiency (GHD) treatment.
Joachim Woelfle, I. Kreitschmann-Andermahr, C. J. Strasburger, D. B. Pittrow, C. Pausch, D. Schnabel   +5 more
doaj   +2 more sources